The Latest Breaking News from Moderna

While Moderna has outpaced the S&P 500 over the past year, Wall Street analysts maintain a cautious outlook about the stock’s prospects.

Three ETFs with year-to-date performance of 30% or better include a fund focused on drone technology, one targeting nickel miners, and a covered call play.

A personalised mRNA vaccine developed by Moderna and Merck shows lasting benefits for patients with high-risk skin cancer.

COVID-19 vaccine stock Moderna just got its biggest lift in recent memory, moving up 17%. Can MRNA stage a broader recovery, down +90% from its all-time high?

Patients with severe melanoma who received the treatment were 49% less likely to die or have their cancer return, pharmaceutical companies Moderna and Merck announced in five-year findings.

Letter: Dr Carol S Leonard writes that mRNA vaccines are a way forward for those with melanoma, but hopes are dashed by financial cuts

Oracle stock boosted the tech sector on Friday after the company became co-owner of TikTok's U.S. operations.

Black boxes are the FDA’s most serious warning sign and are usually placed on opioid products

Moderna has continued to underperform the Nasdaq Composite over the past year, and analysts remain cautious about the stock’s prospects.

Despite Nvidia’s strong quarterly performance, the broader market struggled on Thursday. A robust U.S. jobs report, showing non-farm payrolls rising by 119,000 in September, dampened hopes for a December rate cut, as traders now see a 64% chance of the Fed holding rates steady.

Are Wall Street analysts favoring Moderna’s stock?